

TABLE OF CONTENTS

February 26, 2007

No. 2030

BUSINESS

- 1 Daiichi Sankyo Gears Up to Become Global Drug Discovery Company
- Aiming at Sales of ¥1.5 Trillion in 2015
- 2,300 MRs in Japan
- Olmesartan to Drive Business: President Shoda
- To Focus on 4 Top Priority Fields in R&D
- Aiming at Sales of ¥260 Bil. in US, ¥70 Bil. in Europe
- 3 DSP Is Seeing Synergistic Effects: President Miyatake
- 5 **NEW PRODUCT**
- DSP: Replagal 3.5 mg for IV Drip Infusion for Fabry Disease
- 6 Kyowa Hakko Achieves Personnel Cost Cutting Target Ahead of Schedule
- 6 Intage Surveying Doctors on MR Calls and Their Impact
- Preminent Leads for Number of MR Calls
- 8 **BUSINESS NEWS IN BRIEF**
- Otsuka Licenses Cannabinoid Cancer Pain Killer from GW Pharm.
- MCHC Integrates 3 Group Companies in Healthcare Field
- Toyobo to Sell GenomIdea's Master Cell Bank
- Nihon Chouzai to Settle Prices by End of March: President Mitsuhashi
- 9 **Seminar**
- Lifecycle Management Needs Improvement in Japan: Mr Hatanaka

R&D

- 10 Regulatory Systems in Japan Need Improvements in 5 Areas: Mr Dunoyer of EFPIA Japan
- China, Korea Offer Better Environment for Biomedical Research
- 11 New Review, Consultation Fees Proposed
- 12 Toxicogenomics Research Project
- DB of 150 Compounds Created by Toxicogenomics Project Team
- GL Needed to Protect Privacy: Dr Toyoshima
- 13 CMIC to Go to the West to Promote Japan-Centered Clinical Trials
- 13 **R&D NEWS IN BRIEF**
- Lecithin-Bound SOD Shows Anti-Cerebral Infarction Effects: LTT Bio-Pharma
- ES Cell Research Has Returned to Basics: Mr Ikegaya of JHSF
- More Info. to Be Disclosed on Clinical Trials: JPMA
- Teijin to Construct New R&D Center
- Viramune Effective for HIV: Boehringer Ingelheim

MEDICAL DEVICES

- 16 Roche Diagnostics Aims for 7.1% Growth in Sales in Bearish Market
- Focusing on Lifestyle-related Diseases
- JMCoE Project Enters 2nd Year

- 16 13 Medical Devices Selected for Priority Review
- 17 **MEDICAL DEVICE NEWS IN BRIEF**
- Vitatron Recalls Pacemakers

REGULATORY

- 17 *Koroshō* Again Calls For Early Price Settlement
- 18 **REGULATORY NEWS IN BRIEF**
- Continuous Infusion of KOGENATE Bayer Approved in EU
- LovenoX sNDA to Receive FDA Priority Review: sanofi-aventis
- Relenza Not Reimbursed When Used for Prevention: *Koroshō*
- Group to Study Abbreviation of Documents Required in Clinical Trials
- New WG to Review Issues Related to Fractionated Plasma Products
- English Translation Available for Residue on Ignition Test Method

SELF-MEDICATION

- 19 OTC Drugs That Meet Today's Needs Are Necessary: Mr Kurokawa
- More Effective Switch OTC Drugs Are Needed
- 45% of Consumers Don't Use OTC Drugs for Minor Illnesses
- 20 METI to Start Health Information Platform Initiative

GENERIC

- 20 JPA Working Out Clear Position Toward Promotion of GE Drugs
- 21 No Marked Rise in Share of Generics from Jun. to Oct. 2006
- 21 Toyama Prefecture Tests Generics from Makers Under Its Control

TOPICS

- 21 - Roger Moore Receives Order of Knight Dannebrog: Novo Nordisk

MEDICAL FACILITIES & NURSING CARE

- 22 Pfizer J-GAP Survey
- 67% of Hypertensive Patients Fail to Reach Targets
- GL Need to Be Revised to Raise Target Achievement Rate
- Ca Blockers Most Widely Used to Treat Hypertension
- 22 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
- Prof. Kurata Stresses Need for Fast-dissolving Tablets
- Preferential Treatment of Pediatricians, OB-GYN to Continue
- JPA Presents Model Guidance, SOPs for Safety Management to Member Pharmacies
- Influenza Epidemic to Reach Peak at Last Part of February